The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a-Magnum™ Hip...
Date First Received: June 13, 2008
Last Updated: June 26, 2009
Verified by: Biomet, Inc., June 2009
Clinical Trial Phase: N/A | Start Date: November 2004
Overall Status: Active, not recruiting
Estimated Enrollment: 249
Brief Summary
Official Title: “A Prospective, Non-Controlled, Clinical Investigation of the M2a-Magnum™ Hip System”
Condition Keyword(s):
The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a-Magnum™ Hip System
Study Type: Observational
Study Design: Cohort, Prospective
Study Primary Completion Date: November 2018
Arms, Groups and Cohorts in this Clinical Trial
- : M2a-Magnum™ Hip System
Outcome Measures for this Clinical Trial
Primary Measures
- Harris Hip Score
- Time Frame: 1 year, 3 years, 5 years, 10 years
Safety Issue?: No
- Time Frame: 1 year, 3 years, 5 years, 10 years
- X-rays
- Time Frame: 1 year, 3 years, 5 years, 10 years
Safety Issue?: No
- Time Frame: 1 year, 3 years, 5 years, 10 years
Secondary Measures
- Incidence of revisions, removals, and/or complications
- Time Frame: Any time
Safety Issue?: Yes
- Time Frame: Any time
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Non-inflammatory degenerative joint disease including: Avascular Necrosis, Diastrophic Variant, Fracture of the Pelvis, Fused Hip, Leg Perthes, Osteoarthritis, Slipped Capital Epiphysis, Subcapital Fractures, Traumatic Arthritis
- Rheumatoid Arthritis
- Correction of Functional Deformity
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
- Revision of previously failed total hip arthroplasty
Exclusion Criteria:
Absolute contraindications include:
- Infection, Sepsis, and Osteomyelitis
Relative contraindications include:
- Uncooperative patient or patient with neurologic disorders that are incapable of following directions
- Osteoporosis
- Metabolic disorders which may impair bone formation
- Osteomalacia
- Distant foci of infections which may spread to the implant site
- Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
- Vascular insufficiency, muscular atrophy, or neuromuscular disease
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: N/A
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Biomet Orthopedics, LLC
Overall Clinical Trial Officials and Contacts
Kenneth J Beres, MD Study Director Clinical Research, Biomet Orthopedics, LLC
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00698347
Study ID Number: Biomet 12380-82
ClinicalTrials.gov Identifier: NCT00698347
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.